Abstract | BACKGROUND: AIMS: METHODS: RESULTS: In the seven patients completing the study, the 24-h output volume was 208.6+/-41.3 and 253.9+/-72.4 ml after lanreotide and placebo, respectively. During the first 6 hours values were 48.1+/-14.7 and 77.6+/-21.4 ml (p=0. 02). No significant difference between treatments was detected in the qualitative composition of 24-h pancreatic secretion, although bicarbonate secretion remained lower after the active drug at all the observation intervals. Peak lanreotide levels were detected 15-30 min after drug injection. Clinical and laboratory tolerability was good. CONCLUSIONS:
Lanreotide induced a statistically significant reduction in the output volume with respect to placebo in the first 6 hours after administration, but not thereafter. The present results encourage a new study to be undertaken in a larger sample and with a multiple dosing scheme of treatment.
|
Authors | M Falconi, C Contro, M Ballabio, C Bassi, R Salvia, P Pederzoli |
Journal | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
(Dig Liver Dis)
Vol. 34
Issue 2
Pg. 127-32
(Feb 2002)
ISSN: 1590-8658 [Print] Netherlands |
PMID | 11926556
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bicarbonates
- Gastrointestinal Agents
- Insulin
- Peptides, Cyclic
- lanreotide
- Somatostatin
- Glucagon
|
Topics |
- Aged
- Bicarbonates
(blood)
- Female
- Gastrointestinal Agents
(administration & dosage, pharmacology)
- Glucagon
(blood)
- Humans
- Injections, Subcutaneous
- Insulin
(blood)
- Male
- Middle Aged
- Pancreas
(drug effects)
- Pancreatic Neoplasms
(surgery)
- Pancreaticoduodenectomy
- Peptides, Cyclic
(administration & dosage, pharmacology)
- Somatostatin
(administration & dosage, analogs & derivatives, pharmacology)
- Treatment Outcome
|